Obsidian Therapeutics CFO reports option holdings

Obsidian Therapeutics, Inc. officer Julie B. Feder, Chief Financial Officer, reported initial beneficial ownership of two stock option awards on common stock.

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. officer Julie B. Feder, Chief Financial Officer, reported initial beneficial ownership of two stock option awards on common stock. Both options have an exercise price of $0.7800 per share and expire on January 20, 2036.

One option covers 2,732,337 underlying shares, with 25% vesting on January 12, 2027 and the remainder vesting in 12 equal quarterly installments thereafter, subject to continued service. The other option covers 271,604 underlying shares, with 50% vesting on September 30, 2026 and the remainder vesting in eight equal quarterly installments, also conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Feder Julie B

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,003,941 contracts (Direct)

Footnotes (2)

1. F1. 25% of the shares underlying this option shall vest and become exercisable on January 12, 2027, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. F2. 50% of the shares underlying this option shall vest and become exercisable on September 30, 2026, with the remainder vesting in eight (8) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option 1 underlying shares: 2,732,337 shares Option 2 underlying shares: 271,604 shares Exercise price: $0.7800 per share +3 more

6 metrics

Option 1 underlying shares 2,732,337 shares Stock Option (Right to Buy) on common stock held directly by CFO

Option 2 underlying shares 271,604 shares Second Stock Option (Right to Buy) on common stock held directly

Exercise price $0.7800 per share Exercise price for both reported stock options

Option expiration date January 20, 2036 Expiration date for both stock option positions

Initial vesting (large option) 25% on January 12, 2027 First vesting tranche for 2,732,337-share option, then 12 quarterly installments

Initial vesting (smaller option) 50% on September 30, 2026 First vesting tranche for 271,604-share option, then eight quarterly installments

Key Terms

Stock Option (Right to Buy), underlying security, vest and become exercisable, quarterly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) on common stock"

underlying security financial

"underlying_security_title: Common Stock as the underlying security"

vest and become exercisable financial

"shares underlying this option shall vest and become exercisable on January 12, 2027"

quarterly installments financial

"remainder vesting in twelve (12) equal quarterly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Obsidian Therapeutics (OBX) disclose about Julie B. Feder on this Form 3?

Obsidian Therapeutics reported that Chief Financial Officer Julie B. Feder holds two stock options on common stock, each with an exercise price of $0.7800 per share and expiring on January 20, 2036, subject to specific vesting schedules.

How many Obsidian Therapeutics (OBX) shares are covered by Julie Feder’s reported stock options?

The Form 3 shows stock options over a total of 3,003,941 underlying common shares: one option for 2,732,337 shares and another for 271,604 shares, all at an exercise price of $0.7800 per share.

What are the vesting terms of Julie Feder’s 2,732,337-share option at Obsidian Therapeutics (OBX)?

For the 2,732,337-share option, 25% vests on January 12, 2027, with the remaining shares vesting in 12 equal quarterly installments thereafter, conditioned on Ms. Feder’s continued service on each vesting date.

What are the vesting terms of Julie Feder’s 271,604-share option at Obsidian Therapeutics (OBX)?

For the 271,604-share option, 50% vests on September 30, 2026, and the remaining 50% vests in eight equal quarterly installments thereafter, subject to Ms. Feder’s continued service on each vesting date.

Does the Obsidian Therapeutics (OBX) Form 3 show any stock sales or purchases by Julie Feder?

The Form 3 lists holding entries for stock options but shows no buy or sell transactions. It is an initial statement of beneficial ownership, not a report of trades in the company’s stock.

What is the exercise price and expiration date of Julie Feder’s stock options at Obsidian Therapeutics (OBX)?

Both reported stock options have an exercise price of $0.7800 per share and an expiration date of January 20, 2036, as disclosed in the derivative holdings data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 07:10 PM Accepted by SEC EDGAR 08/03/2026 - 06:39 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Feder Julie B

(Last) (First) (Middle)

OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	01/20/2036	Common Stock	2,732,337	$0.78	D
Stock Option (Right to Buy)	(2)	01/20/2036	Common Stock	271,604	$0.78	D

Explanation of Responses:

1. 25% of the shares underlying this option shall vest and become exercisable on January 12, 2027, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. 50% of the shares underlying this option shall vest and become exercisable on September 30, 2026, with the remainder vesting in eight (8) equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gabriela Morales-Rivera, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)